Prognostic value of the neutrophil/lymphocyte ratio (NLR) in advanced, non resectable, progressive pancreatic and midgut NET after combine therapy using Lu-177 DOTATOC and CAPTEM

#3826

Introduction: Previous data suggest neutrophil/lymphocyte ratios (NLRs) could be used as prognostic factor in various solid tumors.

Aim(s): To explore potential use of NLRs as predictive factor in group of patients treated combine radioligand therapy RLT and CAPTEM.

Materials and methods: Prospective, single-arm, open-label, case series study using combined therapy based on clinical improvement and RECIST. All (n=21) had completed combine RLT (177Lu DOTATOC) and CAPTEM, clinical follow-up after start of therapy at least 36 months. The exploratory post-hoc analyses evaluated the prognostic value of NLR, in the context of and independently prognostic factor from treatment. Standard Kaplan–Meier method were used to generate PFS based on results of NLR data, during active therapy and then 36-months of follow-up. P values and hazard ratios for prognostic effects were generated using Cox model.

Conference:

Presenting Author: Kolasińska-Ćwikła A

Authors: Ćwikła J, Kolasińska-Ćwikła A, Zrajkowska A, Pałucki J, Seklecka N,

Keywords: Neuroendocrine Tumor, Receptor, Somatostatin, CAPTEM radioligand therapy (RLT), Progression-Free Survival, Neutrophil lymphocyte ratio,